What ASCO 2026’s “Translation” Theme Actually Means When You’re Running a Phase I Oncology Trial

Read article

拯救美国的肿瘤学研究

当初创生物技术或制药公司在美国进行第一次实质性的 I/II 期、II 期或 III 期肿瘤学研究时，时间线通常会延长。 肿瘤学研究很复杂，即使是经验丰富的临床开发领导者也会错过病人入组截止日期。随着新免疫疗法的发展，这种情况变得越来越普遍，需要内部临床操作团队、站点以及所有 CRA…
Read Article

Medelis co-founder Daniel Von Hoff receives prestigious ASCO scientific honor

We are pleased to share the news that…
Read Article

肿瘤学研究延迟完成且超出预算的第一大原因

临床研究中的每个人都了解患者入组对研究成功的重要性。 仅在运营成本上，申办者每个临床研究日平均花费 37,000 美元。 在接受调查时，人们表示他们对临床研究感兴趣。 80% 的人非常愿意或有点愿意参与一项研究。 然而，统计数据表明，患者参加研究的意愿与申办者成功实现患者招募目标的能力之间存在脱节：…
Read Article

ASU launches new Master of Science, Clinical Research Management program

Innovative online program provides convenient specialty training for…
Read Article

Mouse Hematology: A Laboratory Manual

Mike McGarry, Ph.D., our Vice President of Preclinical…
Read Article

Dr. Alan Sandler, Dr. James Cassidy Join Medelis’ Medical Advisory Board

We’re pleased to announce more company news today:…
Read Article

Medelis expands CRO services to medical devices, welcomes Dr. Inder Makin

Today we’re pleased to announce that we're expanding…
Read Article

Big pharma tackles patient recruitment challenges, but we have a long way to go

Yesterday, Pfizer and Private Access, a search technology…
Read Article

IRB Selection Tips from ClinPage

Suz Redfearn at ClinPage recently posted an excellent…
Read Article